Ling Mei1, Qian Hu1, Jing Peng1, Jiaying Ruan1, Juan Zou2, Qin Huang2, Shanling Liu3, He Wang4. 1. Department of Obstetric and Gynecologic, West China Second Hospital, Sichuan University Chengdu 610041, China. 2. Department of Pathology, West China Second Hospital, Sichuan University Chengdu 610041, China. 3. Laboratory of Cell and Gene Therapy, West China Institute of Women and Children's Health, West China Second Hospital, Sichuan University Chengdu 610041, China ; Department of Obstetric and Gynecologic, West China Second Hospital, Sichuan University Chengdu 610041, China. 4. Laboratory of Genetics, West China Institute of Women and Children's Health, West China Second Hospital, Sichuan University Chengdu 610041, China ; Department of Obstetric and Gynecologic, West China Second Hospital, Sichuan University Chengdu 610041, China.
Abstract
BACKGROUND: Histone H2AX phosphorylation is a sensitive marker for DSB which contributes to both genomic instability and cancer treatment. Monitoring its formation may be a sensitive means to monitor cancer progression and treatment effect. OBJECTIVE: To define the role of phospho-H2AX (pH2AX) expression in development and prognosis of epithelial ovarian cancer (EOC). METHODS: The expression of pH2AX in 87 EOC samples and 28 samples of normal ovarian tissues were examined by immunohistochemistry (IHC). The results were semi-quantitatively scored and analyzed by chi-square test. The overall survival time (OS) and disease free interval (DFI) were collected by follow-up and analyzed by Kaplan-Meier analysis. RESULTS: The expression level of pH2AX protein in EOC were higher than that in normal tissues (P<0.001). Among the sensitive cases, high expression of pH2AX was found in 53.2% cases while for resistant cases, high expression rate was 80% (P=0.025). However, pH2AX expression was not significantly correlated with age, histopathological type, tumor differentiation, lymph node metastasis or FIGO stages. Kaplan-Meier analysis found that DFI was negatively correlated with the pH2AX expression, where higher expression of pH2AX resulted in shorter DFI while no OS difference was detected in our study. CONCLUSION: pH2AX may be used to detect EOC at an early stage and identify women at higher risk for relapse.
BACKGROUND: Histone H2AX phosphorylation is a sensitive marker for DSB which contributes to both genomic instability and cancer treatment. Monitoring its formation may be a sensitive means to monitor cancer progression and treatment effect. OBJECTIVE: To define the role of phospho-H2AX (pH2AX) expression in development and prognosis of epithelial ovarian cancer (EOC). METHODS: The expression of pH2AX in 87 EOC samples and 28 samples of normal ovarian tissues were examined by immunohistochemistry (IHC). The results were semi-quantitatively scored and analyzed by chi-square test. The overall survival time (OS) and disease free interval (DFI) were collected by follow-up and analyzed by Kaplan-Meier analysis. RESULTS: The expression level of pH2AX protein in EOC were higher than that in normal tissues (P<0.001). Among the sensitive cases, high expression of pH2AX was found in 53.2% cases while for resistant cases, high expression rate was 80% (P=0.025). However, pH2AX expression was not significantly correlated with age, histopathological type, tumor differentiation, lymph node metastasis or FIGO stages. Kaplan-Meier analysis found that DFI was negatively correlated with the pH2AX expression, where higher expression of pH2AX resulted in shorter DFI while no OS difference was detected in our study. CONCLUSION: pH2AX may be used to detect EOC at an early stage and identify women at higher risk for relapse.
Authors: Brenda J Boersma; Tiffany M Howe; Julie E Goodman; Harry G Yfantis; Dong H Lee; Stephen J Chanock; Stefan Ambs Journal: J Natl Cancer Inst Date: 2006-07-05 Impact factor: 13.506
Authors: Craig H Bassing; Katrin F Chua; JoAnn Sekiguchi; Heikyung Suh; Scott R Whitlow; James C Fleming; Brianna C Monroe; David N Ciccone; Catherine Yan; Katerina Vlasakova; David M Livingston; David O Ferguson; Ralph Scully; Frederick W Alt Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205
Authors: Karen L Novik; John J Spinelli; Amy C Macarthur; Karey Shumansky; Payal Sipahimalani; Stephen Leach; Agnes Lai; Joseph M Connors; Randy D Gascoyne; Richard P Gallagher; Angela R Brooks-Wilson Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier Journal: Nat Rev Cancer Date: 2008-11-13 Impact factor: 60.716
Authors: Eriko Katsuta; Abhisha Sawant Dessai; John Ml Ebos; Li Yan; Toru Ouchi; Kazuaki Takabe Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: I Vazquez-Villaseñor; C J Garwood; P R Heath; J E Simpson; P G Ince; S B Wharton Journal: Neuropathol Appl Neurobiol Date: 2019-06-17 Impact factor: 8.090
Authors: Qianqian Wang; Zhuwu Lu; Jinqi Ma; Qingsong Zhang; Ni Wang; Li Qian; Jun Zhang; Chen Chen; Bei Lu Journal: Oncol Lett Date: 2019-05-27 Impact factor: 2.967